Background: More than 4 million children are exposed annually to sedatives and general anaesthetics (GAs) in the USA alone. Recent data suggest that common GAs can be detrimental to brain development causing neurodegeneration and long-term cognitive impairments. Challenged by a recent US Food and Drug Administration (FDA) warning about potentially neurotoxic effects of GAs in children, there is an urgent need to develop safer GAs. Methods: Postnatal Day 7 (P7) rat pups of both sexes were exposed to six (repeated every 2 h) injections of equipotent hypnotic doses of ketamine or the neuroactive steroid (3b,5b,17b)-3-hydroxyandrostane-17-carbonitrile (3b-OH) for 12 h. Loss of righting reflex was used to assess hypnotic properties and therapeutic index; quantitative caspase-3 immunohistochemistry was used to assess developmental neuroapoptosis; patch-clamp recordings in acute brain slices were used to assess the effects of 3b-OH on neuronal excitability and synaptic transmission. Cognitive abilities of rats exposed to ketamine, 3b-OH, or vehicle at P7 were assessed in young adulthood using the radial arm maze. Results: The neuroactive steroid 3b-OH has a therapeutic index similar to ketamine, a commonly used clinical GA. We report that 3b-OH is safe and, unlike ketamine, does not cause neuroapoptosis or impair cognitive development when administered to P7 rat pups. Interestingly, 3b-OH blocks T-type calcium channels and presynaptically dampens synaptic transmission at hypnotically-relevant brain concentrations, but it lacks a direct effect on g-aminobutyric acid A or glutamate-gated ion channels. 
Current general anaesthetics cause developmental neurotoxicity in animal models and possibly humans, creating a need for novel agents devoid of this effect. A neuroactive steroid (3b-OH) was shown to possess hypnotic potency without causing neuroapoptosis in neonatal rats or delayed neurocognitive deficits. Mechanistic investigations showed that 3b-OH blocks T-type Ca 2þ channels and presynaptic transmitter release without affecting major postsynaptic ligandgated ion channels. This provides a promising lead for development of a novel intravenous anaesthetic without developmental neurotoxic effects.
Current research evidence suggests that early exposure to clinically-used general anaesthetics (GAs) can disturb normal brain development leading to permanent cognitive and behavioural impairments in rodents, 1e4 monkeys, 5e9 and possibly in humans as well. 10e14 Currently used GAs are known to modulate two main neurotransmitter systems in the developing braindg-aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA)dwhich prompted us to propose that GAs with a different cellular mechanism of action might be safer and more promising alternatives. One such alternative is a class of drugs that selectively targets T-type voltage-gated calcium channels (T-channels), known to control neuronal excitability and synaptic transmission. 15 Of particular interest for our study is the neuroactive steroid, (3b,5b,17b)-3-hydroxyandrostane-17-carbonitrile (3b-OH), a potent analgesic and voltage-dependent blocker of neuronal T-currents with minimal effect on voltage-gated Na þ and K þ currents, Ntype and L-type Ca 2þ currents, 16, 17 or recombinant GABA A and NMDA-mediated currents. 18 Using a rat pup model, we demonstrate that 3b-OH effectively blocks T-channel-dependent excitability in thalamocortical and subicular neurones, and dampens a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-mediated excitatory transmission acting presynaptically. Furthermore, when compared with ketamine, a commonly used clinical GA, 3b-OH, is an effective hypnotic that does not cause developmental neuroapoptosis or impair cognitive development even during prolonged administration at the peak of synaptogenesis.
Methods

Animals
Most experiments were performed with postnatal day 7 rat pups (P7) (SpragueeDawley, Envigo, Indianapolis, IN, USA), which is the peak of synaptogenesis and vulnerability to anaesthesia-induced developmental neurotoxicity. 19 Pups were housed with their mother and maintained on a 12-h lightedark cycle at a constant temperature of 21(2) C. For radial arm maze behavioural studies, P45eP70 rats were used. For electrophysiology recordings, rat pups aged P7eP9 were used, except for studies on thalamic neurones, which used P7eP15 rat pups. Animals were housed within accredited animal facilities according to protocols approved by the University of Colorado Anschutz Medical Campus. All animals had ad libitum access to food and water. 
Results
3b-OH is an effective hypnotic
The hypnotic properties of the neuroactive steroid 3b-OH (inset in Fig. 1A ) and ketamine were assessed using loss of righting reflex (LORR) in P7 rat pups injected with either agent at doses from 1 to 80 mg kg À1 intraperitoneally (i.p.). Since the vehicles were saline for ketamine and 2-hydroxypropyl-b-cyclodextrin (b-cyclodextrin) for 3b-OH, we included a third experimental group, ketamineþb-cyclodextrin. Rats in each group received only one dose. Neither vehicle, 15% b-cyclodextrin or saline, caused LORR (data not shown). However, 3b-OH, ketamine (KET), and ketamineþb-cyclodextrin (KETþCYCLO) caused dose-dependent shortening of the time to LORR (Fig. 1A) . Data are provided as mean (SEM). The estimated ED 50 for LORR was 3.2 (0.1) mg kg À1 with 3b-OH, 3.5 (0.2) mg kg À1 with KET and 4.1 (0.4) mg kg À1 with KETþCYCLO (Fig. 1B) .
The estimated ED 50 based on the duration of LORR that was obtained when either agent was injected at doses from 1 to 140 mg kg À1 i.p. was 39 (4) mg kg À1 for 3b-OH, 67 (2) mg kg À1 for ketamine, and 64 (2) for ketamineþb-cyclodextrin (Fig. 1C) . The calculated LD 50 for these cohorts yielded values of 63 (4) mg kg À1 for 3b-OH, 97 (0) mg kg À1 for ketamine and 95 (5) for ketamineþb-cyclodextrin (ketamine and 3b-OH LD curves included in the inset, Fig. 1D ) with corresponding therapeutic indices of~20 and~23 for 3b-OH and ketamineþb-cyclodextrin, respectively.
3b-OH, unlike ketamine, does not cause developmental neuroapoptosis
Repeated ketamine administration for 12 h (every 2 h for a total of six doses) at 20 or 40 mg kg À1 induces significant widespread neuroapoptotic degeneration in P7 rats. 20 We first determined the equipotent dose of 3b-OH based on the LORR experiments. The estimated equipotent single dose of 3b-OH comparable with the lower dose of ketamine (20 mg kg À1 ) was 5 mg kg À1 , whereas the calculated equipotent dose of 3b-OH comparable with the higher dose of ketamine (40 mg kg À1 ) was 10 mg kg À1 (Fig. 1D ).
Using these equipotent doses injected repeatedly six times every 2 h (total of 12 h), we conducted neurotoxicity studies where ketamine was compared with 3b-OH and vehicle. The general condition of all treated animals appeared normal (skin colour and breathing) and, as shown in Supplementary In the CA1-subiculum region, there was 100-to 125-fold higher density of caspase-3 stained neurones compared with vehicle controls (Fig. 2A) . When groups treated with either ketamine 40 mg kg À1 alone or with b-cyclodextrin were compared with those treated with 3b-OH at an equipotent dose of 10 mg kg À1 (3b-OH 10), there was a significant increase in caspase-3 activation. Similar findings were replicated in the thalamic anteroventral nucleus (Fig. 1B) , thalamic lateral nucleus (TL) (Fig. 1C) , and cingulate cortex (Fig. 1D ). Comparable )þb-cyclodextrin were injected in P7 rat pups every 2 h for a total of six injections. Bar graphs on the left show averaged data from multiple experiments; representative images are depicted on the right panels. (A) The CA1-subiculum region exhibits a significant increase in caspase-3 activation when compared with groups treated with 3b-OH (3b-OH 10), ketamine alone (KET 40) or ketamineþb-cyclodextrin (KET 40þCYCLO) (***P<0.001 vs KET 40 and P<0.001 vs KET 40þCYCLO) suggesting that 3b-OH, unlike ketamine, does not cause significant developmental neuroapoptosis. This was confirmed by the finding that activated caspase-3 staining in 3beOHetreated animals was not significantly upregulated compared with saline (SAL) or bcyclodextrin (CYCLO) controls (P¼0.964 vs saline and P¼0.980 vs b-cyclodextrin) (n¼6 pups per data point). (B) In thalamic anteroventral nucleus (TAV) there was minimal caspase-3 activation in vehicle groups, whilst there was a significant increase in caspase-3 activation in ketamine or ketamineþb-cyclodextrin groups compared with vehicle controls (***P<0.001). The level of caspase-3 activation in 3b-OH animals was comparable with vehicle controls and significantly lower than in either ketamine or ketamineþb-cyclodextrin (***P<0.001 vs KET 40 and P<0.001 vs KET 40þCYCLO) groups (n¼6 pups per data point). (C) In thalamic lateral nucleus (TL) there was minimal caspase-3 activation in vehicle groups, whilst there was significant caspase-3 activation in ketamine or ketamineþb-cyclodextrin groups (**P¼0.006 vs SAL and P¼0.009 vs CYCLO). Note that the caspase-3 activation in the 3b-OH group is not significant compared with vehicle controls (n¼6 pups per data point). (D) In the cingulate cortex, there was no difference in caspase-3 activation in the 3b-OH group compared with vehicle controls (P>0.999 vs SAL; P¼0.995 vs CYCLO), but ketamine or ketamineþb-cyclodextrin groups exhibited significant increases in caspase-3 activation compared with vehicle control (***P<0.001 vs SAL and P<0.001 vs CYCLO). 3b-OH does not exhibit neurotoxic potential compared with either ketamine or ketamineþb-cyclodextrin groups (***P<0.001 vs KET 40 and P<0.001 vs KET 40þCYCLO) (n¼6 pups per data point). All statistical analyses were done using one-way analysis of variance with Tukey's post hoc test. Representative photomicrographs shown in the right-side panels depict activated caspase-3 staining in ketamineþb-cyclodextrin compared with 3b-OH or a vehicle. Scale bars in the low magnification images in panels (AeC) are 400 mm, and 800 mm in panel (D) . Scale bars in all high magnification insets are 100 mm. Fig. S1 ). Thus 3b-OH, in contrast to ketamine, did not cause significant developmental neuroapoptosis compared with its vehicle, b-cyclodextrin.
Prolonged exposure of rat pups to 3b-OH, unlike ketamine, does not cause learning impairments later in life Ketamine exposure during brain development causes cognitive impairment later in life. 21, 22 Therefore, we compared the cognitive abilities of young adult rats exposed to saline, bcyclodextrin, ketamine, or 3b-OH. We assessed their spatial working memory using the eight-arm radial arm maze test.
We administered saline, b-cyclodextrin, 3b-OH at 10 mg kg À1 or ketamine at 40 mg kg
À1
, every 2 h for a total of six doses over 12 h in P7 rat pups, and examined overall appearance and daily weight in each group. There was no significant difference between the rats in the four groups (Fig. 3A) .
Ketamine-treated rats were significantly impaired relative to controls treated with saline (*P¼0.028) in terms of days required to reach a criterion demonstrating learning (Fig. 3B) . In contrast, 3beOHetreated rats were indistinguishable from vehicle treated animals (b-cyclodextrin) (Fig. 3C) .
The cumulative percentage analysis (Fig. 3D) showed that the acquisition rate of the ketamine-treated group (blue circles) began to slow compared with saline controls (grey triangles) by the 9th day and remained substantially slower for the remainder of training with significant decreases for Days 13e15 (P¼0.021, Fisher's exact test). In contrast, rats in the 3b-OH group (red squares) displayed learning curves similar to vehicle controls (black triangles).
The cumulative percent scores for ketamine-treated animals relative to recorded cumulative percent scores for other groups were examined using a percent-percent plot (Fig. 3E ), which revealed a large gap (shaded area) in learning ability between ketamine-treated (lower black dotted line and blue symbols) and 3beOHetreated animals (upper black dotted line and red symbols).
Pharmacokinetic studies of 3b-OH in rat pups
In order to conduct proper mechanistic studies in vitro, we measured the plasma and brain concentrations of 3b-OH. For these pharmacokinetic studies, we used a dose of 10 mg kg À1 as that was the higher dose used to conduct morphological studies of developmental neuroapoptosis (Fig. 2) and behavioural studies (Fig. 3) . The plasma and brain concentrations of 3b-OH in P7 rat pups were determined over the course of 120 min after a single 3b-OH injection. 3b-OH was detected as early as 2 min in both plasma and brain homogenate with the peak occurring at 5 and 15 min, respectively, followed by a fairly rapid decrease in plasma levels ( Supplementary Fig. S2 ). The calculated plasma and brain tissue half-lives were 8.2 and 29 min, respectively (Supplementary Table S2 ).
3b-OH blocks native Ca V 3.1 channels in immature brain
Considering our findings that 3b-OH has a similar therapeutic index and produces less neuroapoptosis than ketamine, we examined whether 3b-OH has a unique cellular target compared with currently available anaesthetics known to be neurotoxic. Since low-voltage activated T-type Ca 2þ channels are rapidly emerging as promising therapeutic targets and important modulators of neuronal excitability, they were the initial focus of our mechanistic studies. 16, 17 We further examined the cellular targets of 3b-OH using two in vitro systems, known both to express abundant Ca V 3.1 T-channel isoform, 24 and to be vulnerable to anaesthesia-induced developmental neurotoxicity: (i) thalamocortical neurones in the ventrobasal (VB) nucleus, and (ii) pyramidal neurones in the subiculum.
We found that 3 mM 3b-OH decreased the average amplitude of the low-threshold Ca 2þ spike by~70% in thalamic neurones in the VB nucleus, thus abolishing burst firing ( Fig. 4A and B) , without significantly changing the resting membrane potential [À62.4 (1.8) vs À62.0 (1.3) mV]. This in vitro concentration corresponds well to the total brain concentration achieved 5e30 min after acute injection of 10 mg kg À1 of 3b-OH (inset of Fig. 4A ). Next, we examined the effects of 3b-OH on membrane firing of pyramidal neurones in the rat subiculum. Original traces depicted in Figure 4C show that 3b-OH abolished rebound action potentials generated after a brief hyperpolarising stimulus used to de-inactivate T-channels. This correlated well with inhibition of the amplitude of T-currents at À40 mV as shown in the original traces in Figure 4D and the average bar graph in Figure 4E . These data confirm that Tchannels play a crucial role in regulating neuronal excitability of the immature rat subiculum. 25 3b-OH decreases evoked AMPA-mediated, but not NMDA-mediated excitatory synaptic currents acting presynaptically Next, we recorded evoked inhibitory postsynaptic currents (eIPSCs) and evoked excitatory postsynaptic currents (eEPSCs) in subicular neurones using a paired-pulse protocol (Fig. 5) . We found that 3 mM 3b-OH had very little effect on eIPSC amplitude, decay tau or paired-pulse ratio (PPR) (Fig. 5A and B) . In contrast, 3b-OH decreased the amplitude of AMPA-mediated eIPSCs by~50%, with minimal effect on decay kinetics (Fig. 5C ). The PPR was significantly increased, suggesting a lower release probability of glutamate from presynaptic terminals ( Fig. 5C and D) . Interestingly, this finding was not replicated when we pharmacologically isolated NMDA receptor-mediated eEPSCs ( Fig. 5E and F) , which suggests that immature subicular neurones have differential synaptic expression of AMPA and NMDA receptors.
3b-OH decreases spontaneous GABA release
We next studied spontaneous GABA A -mediated IPSCs (sIPSCs) in pyramidal neurones of rat subiculum. Any changes in frequency of sIPCSs would indicate presynaptic effects, whilst alterations of amplitude or decay kinetics of sIPSCs would indicate postsynaptic effects on GABA A receptors. Representative traces of sIPSCs before (black) and after (red) bath application of 10 mM 3b-OH for 10 min in the same neurone are shown in Figure 6A . We found that acutely applied 3b-OH decreased the frequency sIPSCs by >50% [0.73 (0.10) vs 0.34 (0.06) Hz], which was also evident by the longer inter-event intervals represented by cumulative probability plots (Fig. 6B) . In contrast, 3b-OH induced minimal changes in amplitude and decay tau of sIPSCs (Fig. 6C) .
To exclude possible run-down of sIPSCs or inadequate diffusion of steroid through the tissue slice, we performed a population study of sIPSCs in subicular neurones after slice incubation (for at least 1 h) with either vehicle (control) or 10 mM 3b-OH. We also compared effects of 3b-OH to allopregnanolone (Allo), an endogenous steroid that also blocks Tchannels, 26 and that is also a positive allosteric modulator of GABA A receptors. 27 Representative traces of neurones are depicted in Figure 6D showing vehicle-treated control (black trace), 3b-OH pre-incubated slice (red trace), and Allo preincubated slice (green trace). Consistent with their presynaptic effects, both steroids decreased sIPSC frequency [0.77 (0.11) vs 0.44 (0.05) Hz for 3b-OH; and 0.21 (0.04) Hz for Allo, inset of centage of rats reaching 100% as a function of days of trials was compared for the four groups. The acquisition rate of the ketaminetreated group (KET) was slower than that of saline controls (SAL) by Day 9 and remained substantially slower for the remainder of training. In contrast, rats in the 3b-OH group (closed squares) initially exhibited slightly faster acquisition than the vehicle control groups (SAL and CYCLO). However, by Day 16, their learning was identical to the learning curve of vehicle controls. Unlike rats in the ketamine group, all 3beOHetreated rats completed the task in a manner practically indistinguishable from vehicle controls (n¼7 rats per data point in panels AeD). (E) A percent-percent plot analysis shows that when only 28% of ketamine-treated rats (KET) had reached criterion, roughly half of 3beOHetreated and vehicle control (SAL, CYCLO) rats had mastered the task. Whilst the learning curve of ketamine-treated rats remained flat, both 3beOHetreated and vehicle-treated controls showed steady improvement enabling animals to reach criterion (100%), whilst about 85% of ketamine animals managed to master the task in the allotted time. The learning behaviour of 3beOHetreated rats was similar to that of vehicle controls, resulting in a large gap (shaded area) in learning ability between ketamine-treated and 3beOHetreated animals. Fig. 6E ]. Importantly, 3b-OH had no effect on either amplitude or decay kinetics of sIPSCs, whilst Allo significantly prolonged the decay time constant of sIPSCs~2-fold [40 (1.9) vs 77 (7.5) ms] (Fig. 6F) . Thus, it appears that 3b-OH reduces presynaptic GABA release, but unlike Allo, it is devoid of direct effects on postsynaptic GABA A receptors, even at a relatively high concentration of 10 mM. We conclude that 3b-OH inhibits presynaptic AMPA-mediated eEPSCs and GABA-mediated sIPSCs, whilst NMDA-mediated eEPSCs are generally spared at relevant brain concentrations.
Discussion
Here we show that the neuroactive steroid 3b-OH is a promising injectable hypnotic with suitable pharmacokinetic properties. 3b-OH is a distinct non-selective T-channel blocker devoid of GABA potentiating or NMDA antagonistic properties at hypnotically-relevant brain concentrations, and has a safety profile superior to the commonly used injectable anaesthetic ketamine. Specifically, at equipotent doses, 3b-OH does not exhibit evident neurotoxic properties when used in rat pups at the peak of brain development and does not impair subsequent cognitive development. We propose that a novel class of anaesthetic agents with different cellular targets might be safe and promising alternatives to traditional GAs currently used in paediatric medicine.
The neuroactive steroids modulate neuronal activity whilst causing a variety of behavioural and neuroendocrine changes (e.g. general anaesthesia, analgesia, cognitive, and mood alterations). 28 These changes are mediated primarily by actions at ligand-gated ion channels, with much attention focused on the modulation of GABA A receptors by 5a-reduced steroids like Allo. 28e30 Because all GABAergic GAs share neurotoxic potential, we identified a novel steroid analogue with similar hypnotic potency that is an effective inhibitor of neuronal Tchannels, but lacks GABA-mimetic properties. Prevailing concepts are that common GAs that potentiate inhibitory GABA-gated and/or inhibit NMDA-gated ion channels cause neurodegeneration and possibly other long-term changes in the developing mammalian brain. 31 We reasoned that other relevant targets, including ion channels that regulate neuronal excitability, must be considered in designing new and safer GAs. For example, a family of T-channels play important roles in generating low-threshold spike in the thalamus and other central nervous system regions, as well as supporting excitatory synaptic transmission. 15 For example, neuronal T-channels regulate sleep and wakefulness 32 and are inhibited by relevant concentrations of some GAs. 33e36 Here we report that 3b-OH, a potent T-channel blocker with no direct effect on either GABA-or NMDA-mediated currents, displays good hypnotic properties in rat pups in vivo. Furthermore, unlike ketamine, a commonly used agent in paediatric anaesthesia and sedation, 3b-OH caused neither apoptosis in P7 rats nor long-lasting impairment in neurocognitive development, even after a 12 h exposure. It is generally accepted that GAs affect multiple cellular targets (e.g. GABA A , NMDA, background potassium channels) that act in concert to induce both acute hypnotic and lasting cognitive effects on the brain.
37e39 Studies have also shown the common GA isoflurane at clinically-relevant concentrations inhibits not only native and recombinant T-type currents, but also Ca V 2.3 R-type voltage-gated Ca 2þ currents expressed in the thalamus (reviewed by Orestes and amplitude and decay time constant after the first pulse, and on the paired-pulse ratio (n¼5 neurones, three rats).
Todorovic 36 ). Therefore, the potential utility of voltage-gated Ca 2þ channels as targets for the action of GAs remains an important issue in understanding cellular mechanisms of anaesthetic action. It remains to be determined if other cellular targets besides T-channels contribute to the hypnotic properties of 3b-OH. Nevertheless, our present work has the potential to shift the focus to underappreciated targets such as neuronal T-channels for development of novel and safer GAs. We anticipate that specific targeting of neuronal voltage-gated Ca 2þ channels with neurosteroids can be developed in the near future into an effective therapeutic approach and might overcome problems that have been associated with the use of traditional GAs in the young and most vulnerable patient populations.
An ideal GA should be a good analgesic as well, thus enabling minimal use of opioids or non-steroidal analgesics which have considerable side effects of their own. T-channel antagonists in general, and T-channel-blocking steroid analogues in particular (including 3b-OH), are very effective analgesics, not only for acute nociception, 16, 26 but also for alleviation of chronic pain conditions caused by mononeuropathies 40 and systemic neuropathies 41 (e.g. diabetic painful neuropathy). The vehicle used to dissolve 3b-OH (b-cyclodextrin) improves water solubility of lipophilic drugs 42 and might provide targeted encapsulation of endogenous neuroactive steroids that are positive modulators of GABA A receptors. 43, 44 Hence, we were concerned that diminishing the activity of these or mM 3b-OH (red) had longer inter-event intervals of sIPSCs than the control group (black), as shown by cumulative probability plots (5168 and 7341 events, respectively). The column graph in the inset shows lower frequency for groups treated with 3b-OH (n¼19 neurones, nine rats) and Allo (green) (n¼6 neurones, four rats) compared with control (n¼19 neurones, nine rats). One-way analysis of variance (ANOVA): F 2,41 ¼7.37, P¼0.002; Tukey's post hoc test: P¼0.017 and P¼0.005, respectively. (F) The left bar graph shows that the amplitude of sIPSC events was not affected by different treatments (one-way ANOVA: F 2,41 ¼2.44, P¼0.100). Conversely, the right bar graph shows 500 nM Allo significantly prolonged the decay time constant (tau) compared with both the control and 3b-OH groups (one-way ANOVA: F 2,41 ¼27.62, P<0.001; Tukey's post hoc test: P<0.001 vs both groups). *P<0.05, **P<0.01, and ***P<0.001 vs control group; ###P<0.001 vs 3b-OH group.
other potential lipophilic endogenous modulators of ion channels by b-cyclodextrin encapsulation could contribute to the safety profile of 3b-OH. However, ketamineþb-cyclodextrin had similar hypnotic properties and neurotoxic profiles to ketamine alone, such that 3b-OH's favourable safety was likely not as a result of an encapsulating effect by b-cyclodextrin of endogenous ion channel modulators. Currently used GAs impair developmental synaptogenesis, but are a medical necessity in daily clinical practice. Although protective strategies have been reasonably successful in acutely reducing apoptotic activation, 19, 45 repairing synapse integrity, 4 and mending mitochondrial morphogenesis, 46 the issues with protective strategies remain numerous: limited protection, questionable long-lasting benefits, and added complexity to anaesthesia protocols with potential for unpredictable drug interactions. Thus, addition of protective agents has not provided a 'quick' solution to anaestheticinduced neurotoxicity. Based on the recent public warning by the FDA regarding the safety of GAs in very young children, rational and systematic development of safer GAs based on previously unrecognised cellular targets 47 such as T-channels is justified and could be the best strategy for addressing the current conundrum, considering GA is a necessity that often cannot be avoided in children.
